Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+and CD8+T cells and intratumoral lymphotactin transgene expression

Cancer Research

Volumn 62, Issue 7, 2002, Pages 2043-2051

  Huang, Hui ^a   Li, Fang ^a   Gordon, John R ^a   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOATTRACTANT; FAS LIGAND; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; L SELECTIN; LYMPHOTACTIN; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL KILLING; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNITY; MYELOMA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENE;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, C; CHEMOTACTIC FACTORS, EOSINOPHIL; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE TRANSFER TECHNIQUES; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOKINES; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0036531806     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Treatment of murine glioma by adoptive transfer of ex vivo activated tumor-draining lymph node cells
2. Treatment of subcutaneous tumor with adoptively transferred T cells
3. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
4. Successful adoptive immunotherapy of murine poorly immunogenic tumors with specific effector cells generated from gene-modified tumor-primed lymph node cells
5. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but require down-regulation of L-selectin expression
6. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy
7. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
8. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro
9. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2
10. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for IL-12-induced tumor regression
11. Tumor localization of adoptively transferred Indium-III labelled tumor infiltrating lymphocytes in patients with metastatic melanoma
12. Localization of Indium-III labeled tumor, infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy
13. The next frontier of molecular medicine: Delivery of therapeutics
14. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
15. C-C chemokines, but not the C-X-C chemokines IL-8 and interferon γ inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes
16. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines
17. Chemokines, inflammation and the immune system
18. Properties of the novel proinflammatory supergene "intercrine" cytokine family
19. A new class of membrane-bound chemokine a with CX3C motif
20. Molecular cloning and functional characterization of human lymphotactin
21. Molecular cloning of mXCR1, the murine SCM1/lymphotactin receptor
22. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin
23. Lymphotactin acts as an innate mucosal adjuvant
24. +T cells and neutrophils expressing XCR1 receptors
25. Lymphotactin is produced by NK cells and attracts both NK and T cells in vivo
26. +T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon gamma are cytolytic in vitro and tumoricidal in vivo
27. Mechanisms of rejection induced by tumor cell-targeted gene transfer of IL-2, IL-4, II-7, tumor necrosis factor and interferon γ
28. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer
29. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
30. Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells
31. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
32. Targeting γ interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells
33. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineering with IL-2, IL-4, IL-6, II-7, IL-10, TNF, GM-CSF and IFN gene or admixed with conventional adjuvants
34. +T cells in vivo
35. lowcells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
36. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy
37. +T cells infiltrated within cancer cell as a prognostic factor in human colorectal cancer
38. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficiency
39. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver
40. Adenoviral vectors expressing lymphotactin and IL-2 or lymphotactin and IL-12 synergize to facilitate tumor regression in murine breast cancer models
41. The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4 T cells
42. Relative perforin-and Fas-mediated lysis in T1 and T2 CD8 effector cell populations
43. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas
44. Paracrine cytokine adjuvants in cancer immunotherapy
45. -tumor-infiltrating lymphocytes in human solid tumors
46. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility class II negative tumors
47. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response
48. Rat mammary adenocarcinoma 13762 expressing IFN-γ elicits antitumor CD4 MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo
49. T-Cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors
50. Help for cytotoxic T-cell responses is mediated by CD40 signaling
51. T-Cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
52. +T-helper and a T-killer cell
53. +T cell-dependent tumor eradication in vivo
54. +T cells have a major "post-licensing" role in CTL mediated antitumor immunity